consider gilead hepatitis c cure, sovaldi. the company more than recouped what it paid for the drug in the first year of sales alone. and after five years, the company reaped in excess of $58 billion dollars from sales of the drug, more than five times what it paid to acquire the drug from the start-up that took the initial risk and engaged in the innovation. or consider merck’s immunotherapy drug, keytruda. in 2020 alone, the drug’s sales topped $14 billion, with no signs of